dimethyl({[(2S)-pyrrolidin-2-yl]methyl})amine dihydrochloride | 1638760-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: dimethyl({[(2S)-pyrrolidin-2-yl]methyl})amine dihydrochloride
• 英文别名: N,N-dimethyl-1-[(2S)-pyrrolidin-2-yl]methanamine;dihydrochloride
• CAS: 1638760-25-4
• 化学式: C7H18Cl2N2
• 分子量: 201.13
• InChiKey: WYOMVPNXWDCQRG-KLXURFKVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.14
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• [EN] Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection<br/>[FR] NOUVEAUX COMPOSÉS PYRIDO[2,3-B]INDOLE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION BACTÉRIENNE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018178041A1

  公开（公告）日：2018-10-04

  The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

  本发明涉及式(I)的新化合物，其中R1、R2、R3、R4、R5和R6如本文所述，以及它们的药用盐、对映体或二对映体，以及包括这些化合物的组合物和使用这些化合物的方法。
• Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection
  申请人：Hoffmann-La Roche Inc.

  公开号：US10662203B2

  公开（公告）日：2020-05-26

  The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

  本发明涉及式 (I) 的新型化合物、 其中 R1、R2、R3、R4、R5 和 R6 如本文所述，及其药学上可接受的盐、对映体或非对映异构体，以及包括这些化合物的组合物和使用这些化合物的方法。
• NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3601282B1

  公开（公告）日：2021-07-21
• Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection
  申请人：Hoffmann-La Roche Inc.

  公开号：US20180327425A1

  公开（公告）日：2018-11-15

  The present invention relates to novel compounds of formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.